Jetzt anmelden und diskutieren
Registrieren
Login
DEADLINE: March 16, 2026
NEW YORK, March 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP encourages investors who suffered losses in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) to contact the firm before the lead plaintiff deadline.
WHO IS AFFECTED: Those who purchased Vistagen securities between April 1, 2024 and December 16, 2025 may be entitled to recover damages.
Discuss your case with our attorneys or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
APRIL 1, 2024 — CLASS PERIOD BEGINS
The Company announced enrollment of the first patient in its PALISADE-3 Phase 3 trial. Management stated that initiating the trial was "another major milestone" in the plan to develop and commercialize the drug candidate.
JUNE 11, 2024 — FISCAL YEAR RESULTS AND TRIAL ENHANCEMENTS
The Company published fiscal year 2024 results. Joshua Prince, the Chief Operating Officer, discussed "notable enhancements" and "operational changes" to optimize quality enrollment. The Company described improvements including in-person investigator meetings, rigorous training of sites, and enhanced oversight of study conduct.
NOVEMBER 3, 2025 — TRIAL COMPLETION ANNOUNCED
The Company announced completion of the Phase 3 public speaking challenge study. Management stated that the Company remained "encouraged" by the drug candidate's potential and that the same study design had been used with "certain protocol and operational enhancements."
DECEMBER 17, 2025 — CORRECTIVE DISCLOSURE
The Company disclosed that the Phase 3 study did not demonstrate a statistically significant improvement on the primary endpoint. Management characterized the results as "unexpected" and "inconsistent" with positive outcomes observed in prior studies.
WHAT YOU CAN DO
Check your eligibility to participate or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP
Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
View original content to download multimedia:https://www.prnewswire.com/news-releases/levi--korsinsky-llp-timeline-of-alleged-misrepresentations-in-vistagen-therapeutics-securities-class-action-302681181.html
SOURCE Levi & Korsinsky, LLP
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
